Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04852276
Previous Study | Return to List | Next Study

Analysis of the Immune Response to COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04852276
Recruitment Status : Recruiting
First Posted : April 21, 2021
Last Update Posted : June 2, 2021
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )

Tracking Information
First Submitted Date April 20, 2021
First Posted Date April 21, 2021
Last Update Posted Date June 2, 2021
Actual Study Start Date April 20, 2021
Estimated Primary Completion Date June 30, 2025   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: April 20, 2021)
Change in S and RBD immunoglobulin G (IgG) antibody titer from baseline depending on vaccine manufacturer and platform [ Time Frame: 14-21 days or 21-28 days, depending on vaccine manufacturer and platform ]
To characterize the immune response to COVID-19 vaccination among immunodeficient and immune dysregulated individuals compared to healthy volunteers
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: April 20, 2021)
Incidence of vaccine-associated AEadverse events experienced by immunodeficient individuals compared to healthy volunteers [ Time Frame: Throughout study ]
To characterize the COVID-19 vaccine-associated adverse events among immunodeficient and immune dysregulated individuals compared to healthy volunteers
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Analysis of the Immune Response to COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Official Title Analysis of the Immune Response to COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Brief Summary

Background:

The immune system defends the body against disease and infection. Immune deficiencies are

health conditions that decrease the strength of this response. Vaccines stimulate the immune system to create a defense against a specific type of germ. Researchers want to compare immune system responses to COVID-19 vaccines in people with and without immune deficiencies.

Objective:

To learn about how people with immune deficiencies respond to COVID-19 vaccines.

Eligibility:

People age 12 and older with an immune deficiency who plan to get a COVID-19 vaccine. Healthy volunteers are also needed.

Design:

Participants will be screened with a medical record review.

Participants will give a blood sample before they get their first COVID-19 vaccine. Blood will be drawn from an arm vein using a needle. Blood can be drawn at the NIH, at a local doctor s office, or at a laboratory. It may also be drawn through a fingerstick at home. Participants will also complete 2 online surveys about their health and COVID-19 history.

Participants will give a second blood sample 2 to 4 weeks after they get the vaccine. They will complete 2 surveys about changes in their health and side effects from the vaccine.

If participants get a second (booster) vaccine, they will repeat the blood draw and surveys 3 to 4 weeks later.

Participants may give 3 optional blood samples in the 24 months after their last vaccine. They may also give saliva samples every 2 weeks while they are in the study.

Participation will last from 1 month to 2 years after the participant s last vaccine.

Detailed Description

The novel human severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease (COVID-19). This acute respiratory syndrome is associated with activation of the innate immune system and a hyper-inflammatory response which can lead to life-threatening symptoms. There are a number of primary immunodeficiencies (PIDs) that prevent complete activation of innate immune cells or other pro-inflammatory mediators, as well as secondary immune deficiencies that evoke the same dysfunctional immune response. Because the extent to which these individuals experience COVID-19 is unknown, vaccination against SARS-CoV-2 is critical.

In December 2020, the FDA announced Emergency Use Authorization for two mRNA-based SARS-CoV-2 vaccines. While evaluation of the immune response to these vaccines in healthy volunteers is ongoing, no large-scale characterization of the immune response in immunodeficient individuals has been undertaken. This prospective cohort study will assess and describe the baseline and post-vaccination immune response in individuals with select immune deficiencies compared to healthy volunteers who receive a COVID-19 vaccine, as well as any adverse events (AEs) experienced after either dose. All required study visits for this protocol may be conducted remotely; in-person visits at the NIH are optional. Subjects who have not yet been vaccinated will undergo baseline blood sampling using finger stick microsampler kits and/or venous blood draw within 7 days prior to receiving the vaccine. Additional samples will be collected approximately 21 days after dose 1 and approximately 28 days after dose 2 (if applicable). Optional samples may be collected at 6, 12, and 24 months post-vaccination. If a subsequent booster dose is received while a participant is still on study, blood will again be drawn approximately 28 days after the booster dose. Participants who are able to attend in-person visits at NIH will have optional on-site blood draws 1 and 3 days after doses 1 and 2 (as applicable). Research evaluations will include baseline severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibody titers to the spike (S), nucleocapsid (N), and receptor binding domain (RBD) proteins, to assess pre-vaccination SARS-CoV-2 exposure and evaluate responses to vaccination. Additional immune markers of interest may include presence of autoantibodies, transcriptomic profiling, T-cell receptor (TCR) repertoire, among others. Participants who only submit finger stick home microsampler kits at the timepoints listed above will be evaluated for SARS-CoV-2 antibody titers and autoantibodies only. All subjects will be asked at baseline about prior COVID-19 diagnosis, symptoms, and severity, and will be asked additional questions at follow-up timepoints about vaccine AEs using standardized questionnaires.

The goal of this protocol is to gain a comprehensive understanding of the variety of immune responses in immunodeficient individuals.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Immunodeficient individuals will be recruited from NIAID protocols that evaluate primary or secondary immune deficiencies. Potential subjects will be identified by discussion between the study teams and review of medical and research records if necessary. They may also be referred from community practitioners who see this population.Healthy adult volunteers will be recruited through the NIH Clinical Research Volunteer Program, the Office of Patient Recruitment, MMG Patient Recruitment, ResearchMatch, or BuildClinical. Volunteers will also be recruited from existing NIH protocols. Healthy relatives of immunodeficient participants can be recruited for participation as controls if they meet enrollment criteria.
Condition
  • Immunodeficiencies
  • Immune Dysregulations
Intervention Not Provided
Study Groups/Cohorts
  • Control particpants
    Control participants will be healthy volunteers, and may include unaffected relatives of immunodeficient/dysregulated participants
  • Patients with immunodeficiencies and immune dysregulations
    Affected patients with evidence of a primary or secondary immune deficiency or dysregulation
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: April 20, 2021)
600
Original Estimated Enrollment Same as current
Estimated Study Completion Date June 30, 2025
Estimated Primary Completion Date June 30, 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria
  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet the following criteria:

  1. Aged 12 years and older.
  2. Must meet the definition of affected participant or control participant:

    1. Affected participants must have evidence of a primary or secondary immune deficiency or dysregulation under another NIAID protocol or as documented by an outside physician.
    2. Control participants are healthy volunteers that do not have evidence of a primary or secondary immune deficiency or dysregulation and may include unaffected relatives of affected participants.
  3. Ability to provide informed consent.
  4. Willing to have blood samples stored for future research.
  5. Able to proficiently speak, read, and write English.

EXCLUSION CRITERIA:

Individuals meeting any of the following criteria will be excluded from study participation:

  1. Receipt of any other vaccine within 14 days prior to screening.
  2. Planned non-COVID-19 vaccination within 28 days after COVID-19 vaccination(s).
  3. Self-reported pregnancy, breast feeding, or intention to initiate a pregnancy before day 28 after study vaccination.
  4. Any condition that, in the opinion of the investigator, contraindicates participation in this study (e.g. specific autoinflammatory diseases, interferonopathies).
  5. Self-reported history of HIV.
Sex/Gender
Sexes Eligible for Study: All
Ages 12 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts
Contact: Emily E Ricotta, Ph.D. (301) 761-7784 NIAIDCovidVaccineStudy@niaid.nih.gov
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT04852276
Other Study ID Numbers 10000384
000384-I
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )
Study Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators Not Provided
Investigators
Principal Investigator: Emily E Ricotta, Ph.D. National Institute of Allergy and Infectious Diseases (NIAID)
PRS Account National Institutes of Health Clinical Center (CC)
Verification Date May 27, 2021